SEARCH

SEARCH BY CITATION

References

  • Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG et al. (2004). Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 3: 921932.
  • Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ et al. (2008). Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19: 759765.
  • Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD et al. (2009). The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330: 932938.
  • Austin CD, Wen X, Gazzard L, Nelson C, Scheller RH, Scales SJ (2005). Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci U S A 102: 1798717992.
  • Bai RL, Pettit GR, Hamel E (1990). Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265: 1714117149.
  • Boswell CA, Brechbiel MW (2007). Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 34: 757778.
  • Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP et al. (2010a). Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharmaceutics 7: 18481857.
  • Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA (2010b). Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21: 21532163.
  • Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP et al. (2011a). Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS ONE 6: e17874.
  • Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle N, Kozak K et al. (2011b). Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 22: 19942004.
  • Boswell CA, Bumbaca D, Fielder PJ, Khawli LA (2012a). Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J 14: 612618.
  • Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA et al. (2012b). Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 53: 14541461.
  • Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE et al. (2011). Maximizing anti-neuropilin-1 tumour exposure requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol 10: 14765381.
  • Burris HA (2011). Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 11: 807819.
  • Carter PJ, Senter PD (2008). Antibody-drug conjugates for cancer therapy. Cancer J 14: 154169.
  • Chames P, Van Regenmortel M, Weiss E, Baty D (2009). Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157: 220233.
  • Corey E, Vessella RL (2007). Xenograft models of human prostate cancer. In: Chung LWK , Isaacs WB , Simons JW (eds). Prostate Cancer: Biology, Genetics, and the New Therapeutics, 2nd edn. Humana Press: Totowa, NJ, pp. 331.
  • Corey E, Quinn JE, Vessella RL (2003). A novel method of generating prostate cancer metastases from orthotopic implants. Prostate 56: 110114.
  • Davies B, Morris T (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 10931095.
  • Denmeade SR, Isaacs JT (2002). A history of prostate cancer treatment. Nat Rev Cancer 2: 389396.
  • Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K et al. (2009). Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114: 27212729.
  • Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF et al. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21: 778784.
  • Doronina SO, Bovee TD, Meyer DW, Miyamoto JB, Anderson ME, Morris-Tilden CA et al. (2008). Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 19: 19601963.
  • Ducry L, Stump B (2010). Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21: 513.
  • Feldman BJ, Feldman D (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 3445.
  • Foyil KV, Bartlett NL (2011). Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 3: 475485.
  • Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF et al. (2003). cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102: 14581465.
  • Glynne-Jones E, Harper ME, Seery LT, James R, Anglin I, Morgan HE et al. (2001). TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 94: 178184.
  • Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT (2007). Imaging prostate cancer: a multidisciplinary perspective. Radiology 243: 2853.
  • Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277300.
  • Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S et al. (2008). Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26: 925932.
  • Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 15771579.
  • Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE et al. (2005). Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 44: 351364.
  • Lewis MR, Kao JY, Anderson AL, Shively JE, Raubitschek A (2001). An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem 12: 320324.
  • Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA (2009a). Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin 59: 379390.
  • Lin K, Lou T, Ferl G, Leipold D, Graham R, Kozak KR et al. (2009b). Cross-species pharmacokinetic characterization of antibody drug conjugate TenB2-vc-E to understand target biology. AAPS Meeting Abstracts 2009.
  • McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 15731576.
  • Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA (2004). Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res 64: 14601467.
  • Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M (1984). Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 142: 6878.
  • Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR (2008). Management of complications of prostate cancer treatment. CA Cancer J Clin 58: 196213.
  • Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S et al. (2012). Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 11: 752762.
  • Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I et al. (2007). Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia 9: 10991110.
  • Ravizzini G, Turkbey B, Kurdziel K, Choyke PL (2009). New horizons in prostate cancer imaging. Eur J Radiol 70: 212226.
  • Regino CA, Wong KJ, Milenic DE, Holmes EH, Garmestani K, Choyke PL et al. (2009). Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiopharm 2: 917.
  • Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM et al. (1995). Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res 55 (Suppl. 23): 5714s5720s.
  • Rosenthal SA, Sandler HM (2010). Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol 7: 3138.
  • Senter PD (2009). Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13: 235244.
  • Shepard DR, Raghavan D (2009). Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol 7: 1321.
  • Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C et al. (2008). Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem 19: 16731683.
  • Teicher BA (2009). Antibody-drug conjugate targets. Curr Cancer Drug Targets 9: 9821004.
  • Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P et al. (2005). Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res 65: 28462853.
  • Zhao XY, Liu HL, Liu B, Willuda J, Siemeister G, Mahmoudi M et al. (2008). Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. Transl Oncol 1: 102109.
  • Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J et al. (2009). In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther 8: 29372946.